🧾 What This Document Is

This is the annual report (Form 10-K) for Sharps Technology, Inc. for the year ended December 31, 2025. It’s a comprehensive filing required by the SEC that details the company’s business, financial performance, and risks. Think of it as a company’s official yearly report card and self-assessment, filed for investors and regulators to review.

👉 In short: This document explains what the company does, how much money it made or lost, and what challenges it faces. For Sharps, it reveals a massive strategic pivot that defines its entire story.

🏢 What The Company Does

Sharps Technology is undergoing a dramatic transformation. Historically, it was a medical device company focused on safety syringe products. However, its business model has fundamentally shifted.

👉 In simple terms: The company is now primarily a digital asset treasury and investment firm, with its core strategy centered on acquiring and holding Solana (SOL), the native cryptocurrency of the Solana blockchain. Its legacy medical device business is now a smaller segment.

Business Model: It generates revenue from selling and distributing syringes and, increasingly, from the appreciation and staking rewards of its SOL holdings.
Industry: It now operates in two sectors: medical device packaging and digital assets/cryptocurrency.

💰 Financial Highlights (Year Ended Dec 31, 2025)

The financials tell a story of massive losses driven by the volatility of its new strategy.

Net Loss: $282.5 million, a huge increase from a loss of $9.3 million in 2024. This loss is largely tied to the fair value adjustments of its SOL holdings.
Accumulated Deficit: $316.9 million as of year-end, meaning the company has lost more money than it has ever earned over its lifetime.
Cash & Digital Assets: The company’s financial position is now dominated by its crypto holdings. As of the filing, it holds approximately 2,000,000 SOL tokens.
Revenue from Legacy Business: The company generated very limited revenues from its medical device sales and distribution activities.

👉 Why it matters: The company’s bottom line is now heavily tied to the price of SOL. When SOL’s price drops, the company reports significant accounting losses. This creates extreme volatility in its financial results.

🚀 Key Moves & Strategic Pivot

The year was defined by aggressive financial engineering and a complete strategic U-turn.

SOL Acquisition Strategy: The company executed a "Digital Asset Treasury Policy," raising capital specifically to buy and hold SOL. This is now its primary focus.
Massive Capital Raises:
- ATM Offering: It set up a "Controlled Equity Offering" to sell up to $236.6 million of its stock. In 2025, it sold 2.16 million shares, raising $19.3 million in net proceeds.
- Other Offerings: It conducted multiple private placements and securities purchase agreements throughout the year to fund its SOL purchases.
Share Repurchase Program: In October 2025, the Board authorized a program to buy back up to $100 million of its own stock. Through the filing date, it had spent $1.59 million repurchasing 867,678 shares.
Litigation Settlement & Spinoff: In October 2025, the company settled a lawsuit by transferring its Hungarian subsidiary (Safegard Medical Kft) and related patents/trademarks to the opposing party.

📦 Financial Position & Balance Sheet

The company’s balance sheet now looks more like a crypto fund’s than a manufacturer’s.

Assets: Dominated by Digital Assets (the SOL tokens) and some cash from recent raises. Traditional manufacturing equipment is a minor part of the asset base.
Debt & Financing: The company has financed its activities primarily through equity and warrant issuances, not traditional debt. This means it has diluted existing shareholders significantly to raise money.
Why the Pivot? Management believes SOL has technical advantages (speed, scalability) and that holding it offers a strategic treasury opportunity. They are also earning yield by "staking" their SOL.

🔮 What's Next (Strategic Direction)

The future path is clear but fraught with risk.

Primary Objective: Continue to acquire and hold SOL as a core treasury asset.
Operational Focus: Maintain and grow the medical device distribution business as a secondary, legacy operation.
Capital Strategy: Potentially use its "at-the-market" (ATM) equity program and other means to raise further capital for SOL purchases and working capital.
Staking: Actively participate in the Solana network by staking SOL to earn rewards, contributing to network security and generating income.

⚖️ Big Picture: Strengths & Risks

👍 Strengths:

Bold Strategy: Unafraid to make a drastic pivot in pursuit of a new opportunity.
First-Mover in Crypto Treasury: Following a path blazed by companies like MicroStrategy, but focused on SOL instead of Bitcoin.
Access to Capital Markets: Has established mechanisms (like the ATM) to raise funds quickly.

⚠️ Significant Risks:

Extreme Volatility: The company’s financial health and stock price are now directly correlated to the highly volatile cryptocurrency market.
Regulatory Uncertainty: The legal landscape for cryptocurrencies and staking is unclear and evolving, posing a major threat.
Execution Risk: Managing a crypto treasury requires new expertise and carries risks like security breaches, key loss, and platform failures.
Dilution: Continuous fundraising through stock sales will dilute existing shareholders.
Nasdaq Delisting Risk: Must maintain minimum share price and market cap requirements.
Legacy Business Challenges: The medical device industry remains competitive and heavily regulated.

🧠 The Analogy

Sharps Technology is like a former factory owner who sold their machinery to buy a flock of rare, high-value racing pigeons. Their fortune now rises and falls with the unpredictable prize money and breeding market for those pigeons, while the old factory gathers dust as a side business. They’ve made a huge bet that their pigeons (SOL) are the fastest and will win the big races (appreciate in value), but they’re also exposed if the birds get sick, fly away, or the rules of the race change.

📇 Key Contacts & People

Company Address: 105 Maxess Road, Suite 124, Melville, NY 11747
Phone: (631) 574-4436
Website: www.sharpstechnology.com
Directors & Executive Officers: The filing includes details on compensation, transactions, and security ownership for individuals like Alan Blackman and Paul Danner.

🧩 Final Takeaway

Sharps Technology has completely reinvented itself from a medical device maker into a publicly traded vehicle for investing in Solana (SOL). This is a high-risk, high-reward strategy that makes the company’s stock a proxy for the performance of the SOL cryptocurrency. Investors are no longer buying into a syringe business, but into a大胆的加密货币财务策略。

Sharps Technology Inc. — 10-K Filing